Strike,

I agree with your statement "Someone who understands the two major products that CardioGenics has, in particular the Analyzer....will come to the conclusion that CGNH is significantly undervalued." Unfortunately IMO this undervaluation is the result of inept management by Cardiogenics.

Unfortunately Dr G and the Board of Directors have consistently failed to deliver on their public statements regards conduct of the head-to-head trials and they have made IMO patently silly statements regards commercialization of the beads.

IMO "The only remaining question is ..." not "... whether they will have the necessary financing to fulfill their goals." But rather will the beads and analyzer perform as promised in head-to-head clinical trials." As I own more than 100,000 shares of Cardiogenics I obviously believe the technologies will perform but I am losing confidence in Cardiogenics current management team to produce the data that proves the promise is real!

Ante